insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

BFNH · Bioforce Nanosciences Holdings, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D----------
SG&A$12.0K-$10.2K$17.0K$27.7K-$16.3K$8.7K$25.1K-
Total Operating Expenses$117.7K-$115.9K$122.8K$133.5K-$122.0K$114.4K$130.8K-
D&A----------
Operating Income($133.5K)-($122.0K)($114.4K)($133.5K)-----
Interest Expense----------
Income Tax----------
Net Income($102.4K)-($115.9K)($122.8K)($934.6K)-($122.0K)($114.4K)($130.8K)-
EPS - Basic$0.00-$0.00$0.00($0.03)-$0.00$0.00$0.00-
EPS - Diluted$0.00-$0.00$0.00($0.03)-$0.00$0.00$0.00-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$6.3K$786$784$905$13.8K$862$1.6K$667$640$638
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$6.3K$786$784$905$13.8K$862$1.6K$667$640$638
Total Assets$6.3K$786$784$905$13.8K$862$1.6K$667$640$638
Current Liabilities$727.3K$619.3K$500.7K$384.9K$275.0K$2.30M$2.18M$2.07M$1.95M$1.82M
Long-term Debt----------
Total Liabilities$727.3K$619.3K$500.7K$384.9K$275.0K$2.30M$2.18M$2.07M$1.95M$1.82M
Stockholders' Equity($721.0K)($618.5K)($499.9K)($384.0K)($261.2K)($2.30M)($2.18M)($2.06M)($1.95M)($1.82M)
Retained Earnings($162.51M)($162.41M)($162.29M)($162.18M)($162.05M)($161.12M)($161.00M)($160.87M)($160.76M)($160.63M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow$7.1K---($15.2K)---($17.6K)-
Investing Cash Flow----------
Financing Cash Flow($1.5K)---$28.2K---$17.6K-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-1613.5%--14785.1%-13567.0%-6773.3%--7463.2%-17157.4%-20439.5%-
Return on equity14.2%-23.2%32.0%357.8%-5.6%5.5%6.7%-
Return on invested capital----------
Liquidity
Current ratio0.010.000.000.000.050.000.000.000.000.00
Quick ratio0.010.000.000.000.050.000.000.000.000.00
Cash ratio0.010.000.000.000.050.000.000.000.000.00
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier-0.01-0.00-0.00-0.00-0.05-0.00-0.00-0.00-0.00-0.00
Liabilities / Assets114.59787.95638.68425.3319.932671.061333.373096.063047.942852.46
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)0.0%---------
Net income growth (YoY)89.0%-5.0%-7.3%-614.5%--7.4%-0.4%-0.6%-
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-176.0%73.1%77.1%81.4%86.6%-26.5%-27.8%-29.7%-32.0%-35.0%

Peer comparison

Same SIC group: Laboratory Analytical Instruments

CompanyRevenue (last FY)Net marginROE
AVTR$6.55B-8.1%-9.5%
QTRX$138.90M-77.1%-36.2%
ILMN$4.34B19.6%31.2%
A---
CTKB$201.49M-33.0%-19.5%

Comparing BIOFORCE NANOSCIENCES HOLDINGS against the 5 most active filers in the same SIC group.